AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Cidara Therapeutics Inc (NASDAQ:CDTX)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 221.38 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 24.400/10.004 |
| EBITDA (in USD) | -30.107M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -23.90 |
| Total Assets (in USD) | 68.53M |
|---|---|
| Total Liabilities (in USD) | 76.74M |
| Revenue TTM (in USD) | 53.87M |
| Cash (in USD) | 35.778M |
| Market Cap (in USD) | 246.235 M |
| Revenue Per Share TTM | 11.875 |
| Gross Profit TTM (in USD) | -11.232M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Cidara Therapeutics Inc
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Employees: 69
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Jeffrey L. Stein Ph.D. | Pres, CEO & Exec. Director | 1955 |
| 2. | Dr. Taylor Sandison | Chief Medical Officer | 1972 |
| 3. | Dr. Les Tari Ph.D. | Chief Scientific Officer | NA |
| 4. | Dr. Kevin M. Forrest Ph.D. | Founder and Chief Strategy Officer | 1977 |
| 5. | Dr. Preetam Shah M.B.A., Ph.D. | CFO, Chief Bus. Officer & Principal Accounting Officer | 1973 |
| 6. | Mr. Shane M. Ward | COO & Chief Legal Officer | 1975 |
| 7. | Ms. Allison Lewis CCP, SPHR | VP of HR | NA |
| 8. | Mr. James M. Balkovec | Sr. VP of Research | NA |
| 9. | Ms. Laura A. Navalta | Sr. VP of Clinical Operations | NA |
| 10. | Ms. Carol Waldo | Sr. VP of Regulatory Affairs & Quality Assurance | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.010 0.021% | 48.385 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.210 0.431% | 48.7 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+0.520 0.110% | 467.09 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.730 0.112% | 646.48 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -29.527M | -42.467M | -72.111M | -41.092M | -59.016M |
| Minority Interest | - | - | - | - | - |
| Net Income | -29.799M | -43.909M | -72.373M | -40.085M | -59.016M |
| Selling General Administrative | 18.486M | 18.74M | 15.899M | 16.238M | 14.143M |
| Gross Profit | 64.288M | 49.572M | 12.067M | 20.915M | -49.142M |
| Reconciled Depreciation | 1.225M | -1.23M | 0.286M | 0.328M | 0.523M |
| Ebit | -30.943M | -41.025M | -71.849M | -41.724M | -67.659M |
| Ebitda | -29.718M | -42.255M | -71.62M | -42.135M | -67.136M |
| Depreciation And Amortization | 1.225M | -1.23M | 0.229M | -0.411M | 0.523M |
| Operating Income | -29.718M | -42.255M | -71.849M | -41.724M | -63.285M |
| Other Operating Expenses | 94.006M | 91.827M | 83.916M | 62.639M | 63.285M |
| Interest Expense | 0.191M | 0.212M | -0.262M | 0.221M | 0.629M |
| Tax Provision | 0.272M | - | - | - | - |
| Interest Income | - | - | - | 0.632M | - |
| Net Interest Income | 0.191M | -0.212M | -0.262M | 0.221M | 0.629M |
| Income Tax Expense | 0.272M | 1.442M | 0.262M | -1.007M | 4.269M |
| Total Revenue | 64.288M | 49.572M | 12.067M | 20.915M | 0M |
| Total Operating Expenses | 94.006M | 91.827M | 83.916M | 62.639M | 63.285M |
| Cost Of Revenue | - | - | - | 46.401M | 49.142M |
| Total Other Income Expense Net | 0.191M | -0.212M | -0.262M | 0.632M | 3.64M |
| Net Income From Continuing Ops | -29.799M | -42.467M | -72.111M | -41.092M | -59.016M |
| Net Income Applicable To Common Shares | -29.799M | -42.467M | -74.873M | -41.092M | -69.345M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 68.53M | 47.593M | 75.325M | 60.424M | 68.976M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.734M | 6.53M | 6.662M | 10.104M | 5.546M |
| Total Liab | 76.74M | 50.497M | 53.752M | 49.709M | 31.141M |
| Total Stockholder Equity | -8.21M | -2.904M | 21.573M | 10.715M | 37.835M |
| Other Current Liab | 37.251M | 12.594M | 15.057M | 12.169M | 7.726M |
| Common Stock | 0.009M | 0.007M | 0.007M | 0.004M | 0.003M |
| Capital Stock | 0.009M | 0.007M | 0.007M | 0.004M | 0.003M |
| Retained Earnings | -441.431M | -406.966M | -377.167M | -334.7M | -259.827M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 1.084M | 2.891M | 1.101M |
| Cash | 35.778M | 32.731M | 62.273M | 35.912M | 60.268M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 67.418M | 29.972M | 34.017M | 38.564M | 30.199M |
| Current Deferred Revenue | 25.095M | 14.614M | 13.92M | 13.865M | 9.803M |
| Net Debt | -30.901M | -31.414M | -57.212M | -27.95M | -48.543M |
| Short Term Debt | 1.3M | 1.317M | 3.739M | 7.962M | 10.783M |
| Short Long Term Debt | - | - | 2.591M | 7.023M | 9.965M |
| Short Long Term Debt Total | 4.877M | 1.317M | 5.061M | 7.962M | 11.725M |
| Other Stockholder Equity | 433.212M | 404.055M | 398.733M | 345.411M | 297.659M |
| Property Plant Equipment | - | 0.222M | 2.543M | 0.342M | 0.429M |
| Total Current Assets | 60.855M | 45.094M | 71.698M | 57.191M | 65.814M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 16.246M | 5.833M | 5.356M | 11.175M | 5.546M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 6.097M | - | -2.593M | - | -5.546M |
| Accounts Payable | 3.772M | 1.447M | 1.301M | 4.568M | 1.887M |
| Accumulated Other Comprehensive Income | - | - | - | - | -2.842M |
| Non Currrent Assets Other | 1.048M | 1.072M | 1.084M | 2.023M | 1.101M |
| Non Current Assets Total | 7.675M | 2.499M | 3.627M | 3.233M | 3.162M |
| Capital Lease Obligations | 4.877M | 1.317M | 2.47M | 0.939M | 1.76M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.118M | -0.041M | -0.186M | -0.035M | 14.478M |
| Total Cashflows From Investing Activities | -0.118M | -0.041M | -0.186M | -0.035M | 14.301M |
| Total Cash From Financing Activities | -0.951M | 44.597M | 37.278M | 14.273M | 56.153M |
| Net Income | -29.799M | -42.467M | -72.111M | -41.092M | -59.016M |
| Change In Cash | -29.542M | 19.324M | -17.319M | -14.294M | 13.749M |
| Begin Period Cash Flow | 62.273M | 42.949M | 60.268M | 74.562M | 60.813M |
| End Period Cash Flow | 32.731M | 62.273M | 42.949M | 60.268M | 74.562M |
| Total Cash From Operating Activities | -28.473M | -25.232M | -54.411M | -28.532M | -56.705M |
| Depreciation | 1.225M | -1.23M | 0.229M | 0.375M | 0.523M |
| Other Cashflows From Investing Activities | - | - | - | - | 14.478M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 1.093M | -6.591M | - | - |
| Sale Purchase Of Stock | 1.642M | - | 11.055M | 9.008M | 6.644M |
| Other Cashflows From Financing Activities | -0.72M | 0.006M | 0.014M | -9.032M | 49.713M |
| Capital Expenditures | 0.118M | 0.041M | 0.186M | 0.035M | 0.177M |
| Change In Working Capital | -3.432M | 14.436M | 13.36M | 7.487M | -0.399M |
| Other Non Cash Items | 0.001M | 0.015M | 0.021M | 0.036M | 0.086M |
| Free Cash Flow | -28.591M | -25.273M | -54.597M | -28.567M | -56.882M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vifag 2002 SICAV | 1 year ago | 24389 |
| 2. | Sun Life CC&L Group Income & Growth Seg | 2 years ago | 17529 |
| 3. | BlackRock Extended Equity Market K | 1 year ago | 10915 |
| 4. | iShares Micro-Cap ETF | 1 year ago | 9874 |
| 5. | Fidelity Total Market Index | 1 year ago | 9297 |
| 6. | Northern Small Cap Core I | 1 year ago | 7600 |
| 7. | Fidelity Series Total Market Index | 1 year ago | 6512 |
| 8. | NT Ext Equity Mkt Idx Fd - NL | 1 year ago | 4397 |
| 9. | NT Quality Small Cap Core | 1 year ago | 3838 |
| 10. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 1 year ago | 3543 |
| 11. | Spartan Extended Market Index Pool E | 1 year ago | 3517 |
| 12. | NT Ext Equity Mkt Idx Fd - L | 1 year ago | 3354 |
| 13. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 121550 |
| 14. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 52387 |
| 15. | A4Investments SICAV SIF ACCI IlanaA2EURH | 1 year ago | 35500 |
| 16. | Fidelity Extended Market Index | 1 year ago | 27328 |
| 17. | Northern Trust Extended Eq Market Idx | 1 year ago | 3354 |
| 18. | Fidelity Nasdaq Composite Index | 1 year ago | 3323 |
| 19. | Vanguard Balanced Index Inv | 1 year ago | 2966 |
| 20. | Vanguard Instl Ttl Stk Mkt Idx InstlPls | 1 year ago | 2739 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RA Capital Management, LLC | 1 year ago | 703080 |
| 2. | Bain Capital Life Sciences Investors, LLC | 1 year ago | 703080 |
| 3. | Bvf Inc | 1 year ago | 703065 |
| 4. | Monashee Investment Management LLC | 1 year ago | 369099 |
| 5. | Checkpoint Capital LP | 1 year ago | 182426 |
| 6. | Vanguard Group Inc | 1 year ago | 180535 |
| 7. | Renaissance Technologies Corp | 1 year ago | 97817 |
| 8. | Alethea Capital Management, LLC | 1 year ago | 79908 |
| 9. | 5AM Venture Management, LLC | 1 year ago | 56725 |
| 10. | Geode Capital Management, LLC | 1 year ago | 52898 |
| 11. | BlackRock Inc | 2 years ago | 48512 |
| 12. | Adage Capital Partners Gp LLC | 1 year ago | 42755 |
| 13. | Northern Trust Corp | 1 year ago | 31787 |
| 14. | Schonfeld Strategic Advisors LLC | 1 year ago | 19500 |
| 15. | Millennium Management LLC | 1 year ago | 13919 |
| 16. | State Street Corp | 1 year ago | 13576 |
| 17. | U.S. Bancorp | 2 years ago | 13103 |
| 18. | UBS Group AG | 1 year ago | 5877 |
| 19. | Tower Research Capital LLC | 1 year ago | 1115 |
| 20. | Acadian Asset Management LLC | 1 year ago | 855 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...